{
    "clinical_study": {
        "@rank": "141197", 
        "arm_group": {
            "arm_group_label": "INCB039110, gemcitabine, nab-paclitaxel", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Test the hypothesis that INCB039110 can be administered safely in combination with\n      gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer."
        }, 
        "brief_title": "Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Cancer", 
            "Metastatic Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Part 1: This is a dose optimization phase designed to find a tolerated regimen that\n      includes the maximum tolerated dose of INCB039110 (within a defined pharmacologic range) in\n      combination with doses of gemcitabine and nab-paclitaxel that have established safety and\n      tolerability in subjects with advanced or metastatic solid tumors.\n\n      Study Part 2: This phase will explore the safety and clinical activity of the regimen\n      identified in Part 1, in subjects with advanced or metastatic pancreatic cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed solid tumor (Part 1) or pancreatic\n             adenocarcinoma (Part 2)\n\n          -  ECOG performance status \u2264 1\n\n          -  Received no more than 1 prior chemotherapy regimen for advanced or metastatic disease\n             (not including neo-adjuvant and/or adjuvant therapy)\n\n          -  There is no restriction on the number of prior non-myelosuppressive   targeted\n             therapies or hormonal agents (eg, EGFR targeted therapy for lung cancer and hormonal\n             therapy for breast cancer or ovarian cancer); targeted and/or hormonal therapy alone\n             will not be considered chemotherapy for the purposes of this study.\n\n          -  Adequate renal, hepatic, and bone marrow function without blood product or\n             hematopoietic growth factor support:\n\n          -  Ability to swallow and retain oral medication\n\n        Exclusion Criteria:\n\n          -  Any known contraindications to the use of gemcitabine or nab-paclitaxel.\n\n          -  Evidence of uncontrolled brain metastases or history of uncontrolled seizures.\n\n          -  Ongoing radiation therapy and/or radiation therapy administered within 28 days of\n             enrollment or ongoing radiotherapy-related toxicities.\n\n          -  Presence of \u2265 Grade 2 neuropathy.\n\n          -  Inability to swallow food or any condition of the upper GI tract that precludes\n             administration of oral medications.\n\n          -  Recent (\u2264 3 months) history of partial or complete bowel obstruction.\n\n          -  Unwillingness to be transfused with blood components.\n\n          -  Known history of Hepatitis B or C infection or HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858883", 
            "org_study_id": "INCB 39110-116"
        }, 
        "intervention": [
            {
                "arm_group_label": "INCB039110, gemcitabine, nab-paclitaxel", 
                "description": "600QD, 400QD, and 300QD", 
                "intervention_name": "INCB039110", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "INCB039110, gemcitabine, nab-paclitaxel", 
                "description": "1000 mg/m2", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "INCB039110, gemcitabine, nab-paclitaxel", 
                "description": "125 mg/m2, 100 mg/m2", 
                "intervention_name": "nab-paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1B Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Inycte Corporation Call Center", 
            "phone": "1-855-463-3463"
        }, 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "William V. Williams, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of the treatment regimen as measured by the number of participants with adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and weekly for Cycle 1 and then Day 1, Week 8 and Week 15 for all subsequent cycles until the End of Treatment visit (approximately 6 months)."
            }, 
            {
                "measure": "Identify the 'Maximum Tolerated Dose (MTD) within a defined dose range for INCB039110 in the combination regimen.", 
                "safety_issue": "Yes", 
                "time_frame": "Each cohort will be observed for a minimum of 28 days."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858883"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentration of tumor specific biomarkers and cytokines before and during treatment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 6 months."
            }, 
            {
                "measure": "Clinical activity as measured by the greatest decrease in tumor burden compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and approximately every two cycles throughout the study until study completion or early termination (approximately 6 months)."
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}